Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Smith & Nephew plc (SNN) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs Smith & Nephew plc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.97, while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.

JEPQSNN
Sector
Income / Options OverlayHealth
52-Week High
$61.46$38.70
52-Week Low
$53.77$28.73
Market Cap
$12.54B
Enterprise Value
$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.

Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN